alexa Efficacy And Safety Of Daclatasvir Plus Asunaprevir Therapy For Taiwanese Patients With Genotype 1b Hepatitis C Virus Infection | 69256
ISSN: 2161-1459

Journal of Clinical & Experimental Pharmacology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

8th World Congress on Pharmacology and Toxicology
July 24-25, 2017 Melbourne, Australia

Chia-Yen Dai
Kaohsiung Medical University, Taiwan
Posters & Accepted Abstracts: Clin Exp Pharmacol
DOI: 10.4172/2161-1459-C1-020
Abstract
All oral Direct Acting Antivirals (DAAs) achieve high Sustained Virological Response (SVR) rates in patients with chronic hepatitis C Virus (HCV) infection. In Asian countries, the dual therapy with Daclatasvir and Asunaprevir was reported well tolerated and achieved high SVR rates in patients with chronic HCV genotype 1b infection. Recently, the dual therapy has been reimbursed by the National Health Insurance in Taiwan. The studies aimed to survey the efficacy and safety of dual therapy with Daclatasvir and Asunaprevir in Taiwanese patients with HCV genotype 1b infection. Total 19 patients (8 males and 11 females, mean age: 65 years) without the NS5A resistance-associated substitution have been treated with dual therapy for 24 weeks and followed up for 12 weeks. All 19 patients achieve negative HCV RNA at end of therapy and at 12 weeks after cessation of therapy (SVR12). The mean (range) baseline AST, ALT and total bilirubin (T-bil) levels were: 80.6 (30-224) IU/L, 89.0 (34-230) IU/L and 0.71 (0.29-1.24) mg/dL, respectively. In all patients, there was neither significant increase of these liver function markers up to 2 times’ upper limit of normal nor acute exacerbation or decompensation at 12 weeks after therapy. The highest AST, ALT and T-bil levels were 39 IU/L, 47 IU/L and 1.21 mg/dL, respectively. We concluded that dual therapy achieved very high SVR rates and was well tolerated in Taiwanese patients with HCV genotype 1b infection. Further results of large number of treated patients are expected.
Biography

Chia-Yen Dai has completed his MD, Master and PhD degrees from Kaohsiung Medical University, Kaohsiung, Taiwan. He is the Director of Health Management Center and Occupational and Environmental Medicine, Kaohsiung Medical University Hospital and a Full Professor of Hepatology, Internal Medicine, College of Medicine, Kaohsiung Medical University. He has published more than 220 papers in reputed journals with more than 50 papers.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version